The role of secretory proteins such as ADAMs and BMPs in patients with diabetes and nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026990

Enrollment

Unknown

Registered

2019-10-28

Start date

2020-01-01

Completion date

Unknown

Last updated

2019-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus and nonalcoholic fatty liver disease

Interventions

Control:N/A

Type 2 diabetes:N/A

NAFLD?:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with newly diagnosed type 2 diabetes and non-alcoholic fatty liver disease.

Exclusion criteria

Exclusion criteria: Patients with ketoacidosis, symptomatic heart failure, malignant disease in the previous 10 years, liver cirrhosis, hypertension, drug fatty liver disease,hepatic and renal failure, or other known major diseases.

Design outcomes

Primary

Measure	Time frame
ADAMs;glucose;Triglycerides;Cholesterol;Free fatty acid;HDL;LDL;Bone morphogenetic protein;Serum secretory protein;	—

Countries

China

Contacts

Public ContactXiaohe Luo

Chongqing Three Gorges Central Hospital

xiaoheluo@163.com+86 13629796135

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026